Dermira (NASDAQ:DERM) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($1.40) by $0.34, Fidelity Earnings reports. The firm had revenue of $11.53 million for the quarter, compared to analyst estimates of $11.07 million. Dermira had a negative net margin of 306.91% and a negative return on equity of 478.29%.
DERM traded down $0.05 during trading on Thursday, reaching $6.95. The company’s stock had a trading volume of 20,974 shares, compared to its average volume of 1,590,976. The company has a quick ratio of 8.08, a current ratio of 8.42 and a debt-to-equity ratio of 4.95. The firm has a fifty day simple moving average of $6.68 and a two-hundred day simple moving average of $8.64. Dermira has a 1 year low of $5.25 and a 1 year high of $15.48. The company has a market cap of $390.03 million, a price-to-earnings ratio of -1.33 and a beta of 1.33.
In other Dermira news, CEO Thomas G. Wiggans bought 23,419 shares of the firm’s stock in a transaction on Monday, August 19th. The shares were acquired at an average cost of $8.54 per share, with a total value of $199,998.26. Following the purchase, the chief executive officer now directly owns 39,666 shares of the company’s stock, valued at approximately $338,747.64. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Matthew K. Fust sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $8.77, for a total transaction of $52,620.00. Following the completion of the transaction, the director now directly owns 11,051 shares in the company, valued at $96,917.27. The disclosure for this sale can be found here. Company insiders own 12.40% of the company’s stock.
A number of brokerages recently weighed in on DERM. Zacks Investment Research raised shares of Dermira from a “hold” rating to a “strong-buy” rating and set a $6.50 price target on the stock in a research note on Wednesday, October 9th. Leerink Swann decreased their price target on shares of Dermira from $23.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Dermira in a research note on Friday, October 18th. Finally, BidaskClub raised shares of Dermira from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 19th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Dermira currently has an average rating of “Buy” and an average price target of $17.12.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Featured Article: Why are trading ranges significant?
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.